Fever News and Research

RSS

Researchers discover Hyalomma ticks in migratory birds

A type of haemorrhagic fever (Crimean-Congo) that is prevalent in Africa, Asia, and the Balkans has begun to spread to new areas in southern Europe. Now Swedish researchers have shown that migratory birds carrying ticks are the possible source of contagion.

22 Oct 2012

Chinese herbs may show significant benefits for patients with NSCLC, IPF and influenza

Chinese herbs, including JHQG, BFXL, and BFHX, may show significant benefits for patients with non-small cell lung cancer (NSCLC), idiopathic pulmonary fibrosis (IPF), and influenza.

22 Oct 2012

MRSA-related pneumonia can be effectively treated in half the recommended time

The national practice guideline for treating MRSA-related pneumonia is seven to 21 days. A Henry Ford Hospital study found that effective treatment can be done in half the time.

20 Oct 2012

Henry Ford study evaluates length of treatment for MRSA-related pneumonia

The national practice guideline for treating MRSA-related pneumonia is seven to 21 days. A Henry Ford Hospital study found that effective treatment can be done in half the time.

20 Oct 2012

UCI, Brown work advances quest for novel treatments for inherited disorder

UC Irvine and Brown University researchers have created a new fruit fly model of inherited epilepsy that's providing insights into the mechanisms underlying temperature-dependent seizures while establishing a platform from which to develop therapies for these disorders.

20 Oct 2012

New data shows influenza-associated deaths among children, effectiveness of school vaccinations

New data being presented at IDWeek 2012TM shows the fatal risk that influenza poses even for children without underlying health conditions and the effectiveness of school-based vaccination programs in protecting student populations.

20 Oct 2012

Sanofi Pasteur files Fluzone sBLA with FDA for treatment of influenza

Sanofi Pasteur, the vaccines division of Sanofi, announced today that it has filed a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for a quadrivalent formulation of its Fluzone (Influenza Virus Vaccine).

20 Oct 2012

Novel therapy that uses human stool is safe and highly effective in treating C.diff infection

A novel therapy that uses donated human stool to treat the deadly and contagious C.diff infection is safe and highly effective, according to a Henry Ford Hospital study.

20 Oct 2012

Tool reveals myeloproliferative neoplasm patient burden

Researchers have devised a tool to accurately assess the extent of symptoms in patients with myeloproliferative neoplasms.

17 Oct 2012

Saint Louis University to participate in PPV23 vaccine trial for pneumonia

Saint Louis University is participating in a multi-site, National Institutes of Health-sponsored clinical trial in older adults of a new vaccine designed to protect against one of the most common types of pneumonia and related diseases such as bloodstream infections and meningitis.

16 Oct 2012

Merck, AiCuris enter licensing agreement for novel HCMV candidates

Merck, known as MSD outside the United States and Canada, and AiCuris today announced that they have entered into an exclusive worldwide licensing agreement for AiCuris' novel portfolio of investigational medicines targeting Human Cytomegalovirus (HCMV), including letermovir (AIC246), an oral, late-stage antiviral candidate being investigated for the treatment and prevention of HCMV infection in transplant recipients.

15 Oct 2012

Financial Times features special report on NTDs

The Financial Times has published a special report on neglected tropical diseases (NTDs) featuring 10 articles examining issues including prevention, research, and treatment.

12 Oct 2012

AACR conference to focus on scientific and lifestyle strategies for cancer prevention

The American Association for Cancer Research will host the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research at the Hilton Anaheim from Oct. 16-19, 2012.

12 Oct 2012

Myths about the influenza vaccine

With cold and flu season upon us, many companies have geared up for what is predicted to be a busy flu season producing 150 million doses of the influenza vaccine, up 17 million from last year.

9 Oct 2012

Wait until infection is confirmed before starting antimicrobials in ICU

Delaying antimicrobial treatment of patients in the surgical intensive care unit who have a suspected hospital-acquired infection does not increase the risk for mortality, and may even be associated with better outcomes than starting antimicrobials before culturing blood, say researchers.

8 Oct 2012

FMCNA urges dialysis patients to get flu shots

With flu season just around the corner, Fresenius Medical Care North America (FMCNA), the nation's leading network of dialysis facilities, is urging dialysis patients to get flu shots to protect themselves against this common infectious disease. In October, FMCNA will begin offering at no cost to all of its dialysis patients and staff, flu vaccinations, which protect against both seasonal flu and H1N1 swine flu.

6 Oct 2012

Progress toward preventing initial and recurrent episodes of C. diff infection

Surgeons are making progress toward preventing initial and recurrent episodes of clostridium difficile colitis (C. difficile or C. diff), a vicious bacterial infection that is estimated to affect about 336,000 people each year, typically patients on antibiotics.

6 Oct 2012

Sublingual immunotherapy highly effective for chronic allergy and asthma sufferers

Could it be that those with allergic rhinitis (hay fever) and childhood nasal allergies can finally get a break from their allergies and their allergy shots? Chicago's leading allergy, asthma, and immunology expert, Dr. Brian Rotskoff, who treats a large number of Chicago pediatric allergy patients, is happy to say, "Yes!"

5 Oct 2012

Top-line data from Pfizer’s Prevenar 13 Phase 3 trial on pneumococcal disease

Pfizer Inc. today announced top-line data assessing immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, absorbed]) in adults 18 to 49 years of age.

5 Oct 2012

First Edition: October 3, 2012

Kaiser Health News staff writer Jordan Rau reports: "Medicare's new readmission penalties for hospitals just got a bit tougher. The Centers for Medicare & Medicaid Services has discovered errors in its initial calculations in August. As a result, 1,422 hospitals with comparatively high readmission rates will lose slightly more money than they were expecting, according to a Kaiser Health News analysis of the revised penalties. Fifty-five hospitals will lose less than were previously told."

3 Oct 2012